Breast cancer systemic therapy	Level of evidence	Recommendation strength
5.1	Adjuvant systemic therapy
5.1.1	Adjuvant endocrine therapy for HR-positive patients[12,28]	I	A
5.1.2	Adjuvant HER2-targeted therapy for HER2-positive patients[12,28]	I	A
5.1.3	Adjuvant chemotherapy for high-risk recurrence patients[12,28]	I	A
5.2	Neoadjuvant systemic therapy
5.2.1	Indications for neoadjuvant therapy
	a. Inoperable breast cancer (T4 or ≥N2)[12,28]	I	A
	b. Large primary tumor patient who desires breast conservation[12,28]	I	A
	c. Evaluation of drug sensitivity in vivo[12,28]	I	A
5.2.2	Strategy for neoadjuvant therapy
	a. Clarify clinical stage, pathological diagnosis, histological grade and molecular characteristics before treatment[12,28]	I	A
	b. Demarcate the tumor bed before treatment[12,28]	I	A
	c. Tumor response should be routinely assessed during treatment[12,28]	I	A
	d. Pathological evaluation for primary tumor and lymph node after treatment[12,28]	I	A

HR: Hormone receptor; HER2: Human epidermal growth factor receptor 2.